Injectable compositions for the controlled delivery of pharmacologically active compound 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO03034988 A2 2003-05-01 [WO200334988]WO03034988 A3 2003-07-31 [WO200334988] / 2003-05-012003-07-31
申请号/申请日
2002WO-US33300 / 2002-10-18
发明人
MURTHY YERRAMILLI V S N;SUVA ROBERT;
申请人
IDEXX LABORATORIES;
主分类号
IPC分类号
A61K-009/00A61K-009/10A61K-031/137A61K-031/138A61K-031/165A61K-031/18A61K-031/245A61K-031/4704A61K-031/496A61K-031/505A61K-031/65A61K-031/7036A61K-031/7048A61K-047/10A61K-047/12A61K-047/14A61K-047/20A61K-047/22A61K-047/26A61K-047/32A61
摘要
(WO200334988) The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds.  The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition.  The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid.  When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time.  Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal.  Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.  Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2001US-60343625 2001-10-19
主权利要求
(WO200334988) 1. What is claimed is: 1. A composition for administration of a pharmacologically active compound to a mammal, comprising: a salt of the pharmacologically active compound with a lipophilic counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable composition that precipitates when injected into water; and wherein the composition releases the active compound over time when injected into the mammal. 2. The composition of claim 1 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 3. The composition of claim 1 wherein the pharmacologically active compound is an antibiotic. 4. The composition of claim 1 wherein the pharmacologically active compound is tilmicosin, oxytetracycline, doxycycline, fluoxetine, roxithromycin, turbinafine or metoprolol. 5. The composition of claim 1 wherein the pharmacologically active compound is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, dibucaine, bupivacaine, benzocaine, tetracaine, acepromazine, itraconazole, tetracyclines, sulfonamides, and aminoglycosides. 6. The composition of claim 1 wherein the lipophilic counterion is a Cι0-C22saturated or un-saturated fatty acid. 7. The composition of claim 1 wherein the lipophilic counterion is a Cιo-Cι8saturated or unsaturated fatty acid. 8. The composition of claim 7 wherein the fatty acid selected from the group consisting of: lauric acid, decanoic acid, myristic acid, oleic acid and linoleic acid. 9. The method of claim 1 wherein the lipophilic counterion is a polycarboxylic acid. 10. The composition of claim 1 wherein the polycarboxylic acid is selected from the group consisting of: sebacic acid, polysebacic acid, polyaspartic acid, polyacrylic acid, and polybenzoic acid. 11. The composition of claim 1 wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or a combination of: pyrrolidone, N- methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, and tetrahydrofurfuryl alcohol. 12. The composition of claim 1 wherein the pharmaceutically acceptable solvent comprises 10% propylene glycol in glycerol formal with or without stabilizers. 13. The composition of claim 1 wherein the pharmaceutically acceptable solvent is triacetin. 14. The composition of claim 1 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 15. The composition of claim 1 wherein the pharmacologically active compound is tilmicosin, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 16. A method of administering a pharmacologically active compound to a mammal comprising: preparing a composition comprising a salt of the pharmacologically active compound and a lipophilic counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable formulation; and injecting the composition into the mammal; wherein at least a portion of the composition precipitates and releases the active compound over time when injected into the mammal. 17. The method of claim 16 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 18. The method of claim 16 wherein the pharmacologically active compound is an antibiotic. 19. The method of claim 18 wherein the antibiotic is tilmicosin, tetracycline, or doxycycline. 20. The method of claim 18 wherein the antibiotic is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, tefracyclines, sulfonamides, and aminoglycosides. 21. The method of claim 16 wherein the lipophilic counterion is a fatty acid. 22. The method of claim 21 wherein the fatty acid is a C10-C22fatty acid. 23. The method of claim 22 wherein the fatty acid is selected from the group consisting of: lauric acid, decanoic acid, myristic acid, oleic acid and linoleic acid. 24. The method of claim 16 wherein the lipophilic counterion is sebacic acid. 25. The method of claim 16 wherein the pharmaceutically acceptable carrier is selected from the group consisting of: pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, and tetrahydrofurfuryl alcohol. 26. The method of claim 16 wherein the pharmaceutically acceptable carrier is triacetin. 27. The method of claim 16 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 28. The method of claim 16 wherein pharmacologically active compound is tilmicosin, the lipophilic counterion is decanoic acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 29. A method of extending the release time of a pharmacologically active compound administered to a mammal comprising, preparing a formulation comprising, a salt of the pharmacologically active compound and a lipophilic counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable formulation; and injecting the formulation into the mammal; wherein at least a portion of the formulation precipitates and releases the active compound over time when injected into the mammal, thereby extending the release time of the pharmacologically active compound. 30. The method of claim 29 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 31. The method of claim 29 wherein the lipophilic counterion is a C 10-C \8 fatty acid. 32. The method of claim 31 wherein the antibiotic is tilmicosin, oxytetracycline, or doxycycline. 33. The composition of claim 32 wherein the fatty acid selected from the group consisting of: lauric acid, decanoic acid, and myristic acid. 34. The composition of claim 29 wherein the lipophilic counter ion is sebacic acid. 35. The composition of claim 29 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 36. The composition of claim 29 wherein the pharmacologically acceptable compound is tilmicosin, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 37. A method of manufacturing an injectable formulation for the administration of a pharmacologically active compound to a mammal comprising, providing a salt of the pharmacologically active compound with a lipophilic counterion; providing a pharmaceutically acceptable solvent; combining the salt and the solvent to form an injectable formulation; wherein at least a portion of the formulation precipitates and releases the active compound over time when injected into the mammal. 38. The method of claim 37 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 39. The method of claim 37 wherein the pharmacologically active compound is an antibiotic. 40. The composition of claim 37 wherein the antibiotic is tilmicosin, oxytetracycline, or doxycycline. 41. The method of claim 37 wherein the lipophilic counterion is a Cι0-C18fatty acid. 42. The method of claim 41 wherein the fatty acid is selected from the group consisting of: lauric acid, decanoic acid, and myristic acid. 43. The method of claim 37 wherein the lipophilic counterion is sebacic acid. 44. The method of claim 37 wherein the pharmaceutically acceptable carrier is selected from the group consisting of: pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, and tetrahydrofurfuryl alcohol. 45. The method of claim 37 wherein the pharmaceutically acceptable carrier is triacetin. 46. The method of claim 37 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 47. The method of claim 37 wherein the pharmacologically active compound is tilmicosin, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 48. The method of claim 37 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 49. A composition for administration of a pharmacologically active compound to a mammal, comprising: a salt of the pharmacologically active compound with a lipophilic counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable composition; and wherein at least a portion of the composition precipitates and releases the active compound over time when injected into an aqueous environment. 50. The composition of claim 49 wherein the pharmaceutically acceptable solvent is water miscible. 51. The composition of claim 49 wherein the antibiotic is tilmicosin, oxytetracycline, or doxycycline. 52. The composition of claim 49 wherein the pharmacologically active compound is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, dibucaine, bupivacaine, benzocaine, tetracaine, acepromazine, itraconazole, tetracyclines, sulfonamides, and aminoglycosides. 53. The composition of claim 49 wherein the lipophilic counterion is a do- Cι8fatty acid. 54. The composition of claim 53 wherein the fatty acid selected from the group consisting of: lauric acid, decanoic acid, and myristic acid. 55. The composition of claim 49 wherein the lipophilic counterion is sebacic acid. 56. The composition of claim 49 wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or a combination of: pyrrolidone, N- methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, and tetrahydrofurfuryl alcohol. 57. The composition of claim 49 wherein the pharmaceutically acceptable solvent is triacetin. 58. A composition for administration of a pharmacologically active compound to a mammal, comprising: a salt of the pharmacologically active compound with a lipophilic counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable composition; and wherein at least a portion of the pharmaceutically active compound and lipophilic counterion dissolves in the solvent and precipitates in vivo. 59. A composition for administration of a pharmacologically active compound to a mammal, comprising: a salt of the pharmacologically active compound with a polycarboxylic acid counterion; and a pharmaceutically acceptable solvent; combined together to form an injectable composition that precipitates when injected into water; and wherein the composition releases the active compound over time when injected into the mammal. 60. The composition of claim 58 wherein the polycarboxylic acid is selected from the group consisting of: polyaspartic acid, polyacrylic acid, sebacic acid, polysebacic acid, and polybenzoic acid. 61. The composition of claim 58 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 62. The composition of claim 58 wherein the pharmacologically active compound is an antibiotic. 63. The composition of claim 58 wherein the pharmacologically active compound is tilmicosin, oxytetracycline, doxycycline, fluoxetine, roxithromycin, turbinafine or metoprolol. 64. The composition of claim 58 wherein the pharmacologically active compound is selected from the group consisting of: trimefhoprim, neomycin, streptomycin, gentamycin, dibucaine, bupivacaine, benzocaine, tetracaine, acepromazine, itraconazole, tefracyclines, sulfonamides, and aminoglycosides.
法律状态
(WO200334988) LEGAL DETAILS FOR WO03034988  Actual or expected expiration date=2005-04-19    Legal state=DEAD    Status=LAPSED     Event publication date=2002-10-18  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS0233300  Application date=2002-10-18  Standardized application number=2002WO-US33300     Event publication date=2003-05-01  Event code=WO/A2  Event type=Examination events  International application published without international search report  Publication country=WO  Publication number=WO03034988  Publication stage Code=A2  Publication date=2003-05-01  Standardized publication number=WO200334988     Event publication date=2003-05-01  Event code=WO/AL  Event indicator=Pos  Event type=Designated states  Designated countries for regional patents GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG    Event publication date=2003-05-01  Event code=WO/AK  Event indicator=Pos  Event type=Designated states  Designated states AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW    Event publication date=2003-07-31  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO03034988  Publication stage Code=A3  Publication date=2003-07-31  Standardized publication number=WO200334988     Event publication date=2003-08-21  Event code=WO/DFPE  Event type=Examination events  Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)    Event publication date=2005-04-19  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE AU2002335077  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=AU Corresponding appl: AU2002335077  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002AU-0335077 Corresponding cc:  Designated or member state=AU Corresponding pat: AU2002335077  Publication stage code in the designated or member state=B2  Publication date in the designated or member state=2006-09-07   Publication number in the designated or member state=AU2002335077    Event publication date=2004-02-16  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=AU     Event publication date=2007-05-24  Event code=AU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=AU  LEGAL DETAILS FOR DESIGNATED STATE BG108634  Actual or expected expiration date=2010-04-30    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=BG Corresponding appl: BG10863404  Application date in the designated or member state=2004-03-16   Application number in the designated or member state=2004BG-0108634 Corresponding cc:  Designated or member state=BG Corresponding pat: BG108634  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-04-30   Publication number in the designated or member state=BG-108634    Event publication date=2004-03-16  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=BG     Event publication date=2004-03-16  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=BG     Event publication date=2005-04-30  Event code=BG/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=BG  LEGAL DETAILS FOR DESIGNATED STATE BR0213425  Actual or expected expiration date=2012-09-04    Legal state=DEAD    Status=REVOKED   Corresponding cc:  Designated or member state=BR Corresponding appl: BR0213425  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002BR-0013425 Corresponding cc:  Designated or member state=BR Corresponding pat: BR0213425  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2004-12-14   Publication number in the designated or member state=BR200213425    Event publication date=2012-12-11  Event code=BR/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=BR  LEGAL DETAILS FOR DESIGNATED STATE CA2463896  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2463896  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002CA-2463896 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2463896  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2003-05-01   Publication number in the designated or member state=CA2463896    Event publication date=2004-04-16  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CA     Event publication date=2010-05-04  Event code=CA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE CN1607937  Actual or expected expiration date=2010-08-11    Legal state=DEAD    Status=REVOKED   Corresponding cc:  Designated or member state=CN Corresponding appl: CN02819284  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002CN-0819284 Corresponding cc:  Designated or member state=CN Corresponding pat: CN1607937  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-04-20   Publication number in the designated or member state=CN1607937    Event publication date=2004-03-30  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=CN     Event publication date=2010-08-11  Event code=CN/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=CN  LEGAL DETAILS FOR DESIGNATED STATE EP1446103  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=EP Corresponding appl: EP02802160  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002EP-0802160 Corresponding cc:  Designated or member state=EP Corresponding pat: EP1446103  Publication stage code in the designated or member state=A2  Publication date in the designated or member state=2004-08-18   Publication number in the designated or member state=EP1446103    Event publication date=2003-06-25  Event code=WO/121  Event type=Designated states  EP: The EPO has been informed by wipo that ep was designated in this application Corresponding cc:  Designated or member state=EP     Event publication date=2004-05-18  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=EP     Event publication date=2004-08-18  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=EP     Event publication date=2016-11-30  Event code=EP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE IL160282  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=IL Corresponding appl: IL16028204  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002IL-0160282 Corresponding cc:  Designated or member state=IL Corresponding pat: IL160282  Publication stage code in the designated or member state=B  Publication date in the designated or member state=2009-11-18   Publication number in the designated or member state=IL-160282    Event publication date=2012-10-31  Event code=IL/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=IL  LEGAL DETAILS FOR DESIGNATED STATE IN0224/KOLNP/2004  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=IN Corresponding appl: IN0224/KOLNP/2004  Application date in the designated or member state=2004-02-18   Application number in the designated or member state=2004IN-KN00224 Corresponding cc:  Designated or member state=IN Corresponding pat: IN0224/KOLNP/2004  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-09-23   Publication number in the designated or member state=IN2004KN00224    Event publication date=2008-04-04  Event code=IN/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=IN  LEGAL DETAILS FOR DESIGNATED STATE JP2005506992  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=JP Corresponding appl: JP2003537557  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2003JP-0537557 Corresponding cc:  Designated or member state=JP Corresponding pat: JP2005506992  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-03-10   Publication number in the designated or member state=JP2005506992    Event publication date=2004-04-13  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=JP     Event publication date=2016-10-18  Event code=JP/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=JP  LEGAL DETAILS FOR DESIGNATED STATE NZ531460  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=NZ Corresponding appl: NZ53146002  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002NZ-0531460 Corresponding cc:  Designated or member state=NZ Corresponding pat: NZ531460  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-05-27   Publication number in the designated or member state=NZ-531460    Event publication date=2004-03-01  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=NZ     Event publication date=2005-05-27  Event code=WO/WWP  Event indicator=Pos  Event type=Examination events  Wipo information: published in national office Corresponding cc:  Designated or member state=NZ     Event publication date=2005-09-08  Event code=WO/WWG  Event indicator=Pos  Event type=Event indicating In Force  Wipo information: grant in national office Corresponding cc:  Designated or member state=NZ  LEGAL DETAILS FOR DESIGNATED STATE RU2004115103  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=RU Corresponding appl: RU2004115103  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2004RU-0115103 Corresponding cc:  Designated or member state=RU Corresponding pat: RU2004115103  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2005-03-20   Publication number in the designated or member state=RU2004115103    Event publication date=2007-02-10  Event code=RU/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=RU  LEGAL DETAILS FOR DESIGNATED STATE ZA200401076  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=ZA Corresponding appl: ZA200401076  Application date in the designated or member state=2004-02-10   Application number in the designated or member state=2004ZA-0001076 Corresponding cc:  Designated or member state=ZA Corresponding pat: ZA200401076  Publication stage code in the designated or member state=B  Publication date in the designated or member state=2005-06-29   Publication number in the designated or member state=ZA200401076    Event publication date=2004-02-10  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=ZA     Event publication date=2005-06-29  Event code=ZA/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=ZA
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部